XtalPi
晶泰科技

QuantumPharm Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2228)

PROPOSED CHANGE OF COMPANY NAME

PROPOSED CHANGE OF COMPANY NAME

The Board proposes to change the English name of the Company from "QuantumPharm Inc." to "XtalPi Holdings Limited" and adopt the Chinese name "晶泰控股有限公司" as the dual foreign name of the Company.

The Proposed Change of Company Name is subject to the following conditions: (i) the passing of a special resolution by the Shareholders at the EGM to approve the Proposed Change of Company Name; and (ii) the Registrar of Companies in the Cayman Islands approving the Proposed Change of Company Name.

GENERAL

A special resolution will be proposed at the EGM to consider and, if thought fit, approve the Proposed Change of Company Name. A circular containing, among other things, details of the Proposed Change of Company Name, together with a notice convening the EGM and the related form of proxy, will be published on the websites of the Company and the Stock Exchange respectively as soon as practicable.

PROPOSED CHANGE OF COMPANY NAME

The board (the "**Board**") of directors (the "**Directors**") of QuantumPharm Inc. (the "**Company**") proposes to change the English name of the Company from "QuantumPharm Inc." to "XtalPi Holdings Limited" and adopt the Chinese name "晶泰控股有限公司" as the dual foreign name of the Company (the "**Proposed Change of Company Name**").

Reasons for the Proposed Change of Company Name

The Company has been using the trade names of "XtalPi" and "晶泰" to conduct daily operations and business development activities for the past decade and therefore has built high brand recognition amongst key stakeholders including some leading pharmaceutical companies in China and globally. The Board considers the proposed change of English Company name to "XtalPi Holdings Limited" and adoption of the Chinese Company name of "晶泰控股有限公司" will provide the Company with a more defined corporate image and identity which will benefit the Company's future business and development both in China and globally. The Board believes that the Proposed Change of Company Name is in the interests of the Company and the shareholders of the Company ("**Shareholders**") as a whole.

Conditions of the Proposed Change of Company Name

The Proposed Change of Company Name is subject to satisfaction of the following conditions:

(a) the passing of a special resolution by the Shareholders approving the Change of Company Name at the forthcoming extraordinary general meeting of the Company (the "**EGM**"); and

(b) the Registrar of Companies in the Cayman Islands approving the Proposed Change of Company Name.

Subsequent to the passing of a special resolution by the Shareholders approving the Proposed Change of Company Name, the Company will carry out the necessary registration and/or filing procedures with the Registrar of Companies in the Cayman Islands. Upon completion of the review by the Registrar of Companies in the Cayman Islands, a certificate of incorporation on change of name will be issued by the Registrar of Companies in the Cayman Islands, certifying the change of the English name of the Company and adoption of the dual foreign name in Chinese of the Company with effect from the date of the passing of the special resolution approving the Proposed Change of Company Name. After the receipt of the certificate of incorporation on change of name issued by the Registrar of Companies in the Cayman Islands, the Company will carry out the necessary registration and/or filing procedures with the Companies Registry in Hong Kong pursuant to Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong).

Effect of the Proposed Change of Company Name

The Proposed Change of Company Name will not affect any rights of the Shareholders or the Company's daily operations or its financial position. Once the Proposed Change of Company Name has become effective, any new share certificates of the Company issued thereafter will bear the new name of the Company.

All the existing share certificates in issue bearing the present name of the Company will, after the Proposed Change of Company Name having become effective, continue to be effective and valid evidence of legal title to the shares of the Company and will continue to be valid for trading, settlement, registration and delivery purposes. Accordingly, there will not be any arrangement for free exchange of the existing share certificates of the Company for new share certificates bearing the new name of the Company.

In addition, subject to the confirmation by the Stock Exchange, the English and Chinese stock short names of the Company for trading of the securities on the Stock Exchange will also be changed after the Proposed Change of Company Name becomes effective.

GENERAL

A special resolution will be proposed at the EGM to consider and, if thought fit, approve the Proposed Change of Company Name. A circular containing, among other things, details of the Proposed Change of Company Name, together with a notice convening the EGM and the related form of proxy, will be published on the websites of the Company and the Stock Exchange respectively as soon as practicable.

To the best knowledge, information and belief of the Directors having made all reasonable enquiries, no Shareholder will be required to abstain from voting on the special resolution for approving the Proposed Change of Company Name.

Further announcement(s) will be made by the Company as and when appropriate to inform the Shareholders of, among other things, the poll results of the EGM, the effective date of the Proposed Change of Company Name and the new English and Chinese stock short names of the Company for trading of the shares of the Company on the Stock Exchange.

By order of the Board
QuantumPharm Inc.
Dr. Wen Shuhao
Chairman of the Board and Executive Director

Hong Kong, 18 October 2024

As at the date of this announcement, the Board comprises Dr. Wen Shuhao, Dr. Ma Jian, Dr. Lai Lipeng and Dr. Jiang Yide Alan as executive Directors, Dr. Gu Cuiping as a non-executive Director, and Mr. Law Cheuk Kin Stephen, Ms. Chan Wing Ki and Mr. Chow Ming Sang as independent non-executive Directors.